Top

Published in:

Open Access 01-05-2020 | Medulloblastoma | Clinical Study

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study

Authors: Linda Dirven, Ralf Luerding, Dagmar Beier, Elisabeth Bumes, Christiane Reinert, Clemens Seidel, Matteo Mario Bonsanto, Michael Bremer, Stefan Rieken, Stephanie E. Combs, Ulrich Herrlinger, Corinna Seliger, Holger Kuntze, Regine Mayer-Steinacker, Annette Dieing, Claudius Bartels, Oliver Schnell, Astrid Weyerbrock, Sabine Seidel, Oliver Grauer, Minou Nadji-Ohl, Frank Paulsen, Michael Weller, Wolfgang Wick, Peter Hau

Published in: Journal of Neuro-Oncology | Issue 1/2020

Abstract

Background

Combined radiochemotherapy followed by maintenance chemotherapy with cisplatin, lomustine and vincristine within the NOA-07 study resulted in considerable short-term toxicity in adult medulloblastoma patients. Here we investigated the long-term impact of this treatment, focusing on neurocognitive functioning and health-related quality of life (HRQoL).

Methods

Neurocognitive functioning and HRQoL scores over time were determined, and differences between the post-treatment and follow-up assessments were calculated up to 18 months for neurocognition and 60 months for HRQoL.

Results

28/30 patients were analyzed. The three preselected HRQoL scales (role, social and cognitive functioning) showed improved scores, to a clinically relevant extent (≥ 10 points), compared to post-treatment levels up to 30 months, but decreased afterwards. Z-scores for verbal working memory were worse during follow-up compared to post-treatment scores and remained impaired during 18 months follow-up (i.e. z-score below − 1 standard deviation). Attention was impaired post-treatment, and remained impaired to a clinically relevant extent during follow-up. Coordination/processing speed and lexical verbal fluency improved compared to post-treatment scores, and remained within the normal range thereafter. Other tests of verbal fluency were stable over time, with z-scores within the normal range.

Conclusions

This long-term follow-up study showed that the NOA-07 treatment regimen was not associated with a deterioration in HRQoL in the post-treatment period. Verbal working memory deteriorated, while other neurocognitive domains did not seem to be impacted negatively by the treatment.

Available only for authorised users

Khanna V, Achey RL, Ostrom QT et al (2017) Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. J Neurooncol 135(3):433–441PubMedCrossRef

Beier D, Proescholdt M, Reinert C et al (2018) Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-oncology 20(3):400–410PubMedCrossRef

Friedrich C, von Bueren AO, von Hoff K et al (2013) Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. Eur J Cancer 49(4):893–903PubMedCrossRef

Kann BH, Lester-Coll NH, Park HS et al (2017) Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-oncology 19(2):259–269PubMed

Wang J, Garancher A, Ramaswamy V, Wechsler-Reya RJ (2018) Medulloblastoma: from molecular subgroups to molecular targeted therapies. Annu Rev Neurosci 41:207–232PubMedCrossRef

Li Q, Dai Z, Cao Y, Wang L (2018) Comparing children and adults with medulloblastoma: a SEER based analysis. Oncotarget 9(53):30189–30198PubMedPubMedCentralCrossRef

Northcott PA, Hielscher T, Dubuc A et al (2011) Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 122(2):231–240PubMedPubMedCentralCrossRef

Remke M, Hielscher T, Northcott PA et al (2011) Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29(19):2717–2723PubMedCrossRef

Brandes AA, Palmisano V, Monfardini S (1999) Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev 25(1):3–12PubMedCrossRef

10.

Millard NE, De Braganca KC (2016) Medulloblastoma. J Child Neurol 31(12):1341–1353PubMedCrossRef

11.

von Bueren AO, Friedrich C, von Hoff K et al (2015) Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol. Eur J Cancer 51(16):2434–2443CrossRef

12.

Douw L, Klein M, Fagel SS et al (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8(9):810–818PubMedCrossRef

13.

Harrison RA, Kesler SR, Johnson JM, Penas-Prado M, Sullaway CM, Wefel JS (2019) Neurocognitive dysfunction in adult cerebellar medulloblastoma. Psycho-oncology 28(1):131–138PubMedCrossRef

14.

De B, Beal K, De Braganca KC et al (2018) Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. J Neurooncol 136(1):95–104PubMedCrossRef

15.

Chevignard M, Camara-Costa H, Doz F, Dellatolas G (2017) Core deficits and quality of survival after childhood medulloblastoma: a review. Neuro-oncol Pract 4(2):82–97CrossRef

16.

Baillieux H, De Smet HJ, Dobbeleir A, Paquier PF, De Deyn PP, Marien P (2010) Cognitive and affective disturbances following focal cerebellar damage in adults: a neuropsychological and SPECT study. Cortex 46(7):869–879PubMedCrossRef

17.

Bostan AC, Dum RP, Strick PL (2013) Cerebellar networks with the cerebral cortex and basal ganglia. Trends Cogn Sci 17(5):241–254PubMedPubMedCentralCrossRef

18.

Timmann D, Daum I (2007) Cerebellar contributions to cognitive functions: a progress report after two decades of research. Cerebellum (London, England) 6(3):159–162CrossRef

19.

Ziemus B, Baumann O, Luerding R et al (2007) Impaired working-memory after cerebellar infarcts paralleled by changes in BOLD signal of a cortico-cerebellar circuit. Neuropsychologia 45(9):2016–2024PubMedCrossRef

20.

von Aster M, Neubauer A, Horn R (2009) Wechsler Intelligenztest für Erwachsene WIE, 2nd edn. Pearson Assessment & Information GmbH, Frankfurt/M

21.

Tombaugh TN (2004) Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19(2):203–214PubMedCrossRef

22.

Benton AL, Hamsher K (1989) Multilingual aphasia examination. AJA Associates, Iowa City, IA

23.

Aschenbrenner S, Tucha O, Lange KW (2000) Regensburger Wortflüssigkeitstest RWT Handanweisung. Hogrefe, Seattle

24.

Beglinger LJ, Gaydos B, Tangphao-Daniels O et al (2005) Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol 20(4):517–529PubMedCrossRef

25.

Heo JH, Lee KM, Paek SH et al (2008) The effects of bilateral subthalamic nucleus deep brain stimulation (STN DBS) on cognition in Parkinson disease. J Neurol Sci 273(1–2):19–24PubMedCrossRef

26.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef

27.

Osoba D, Aaronson NK, Muller M et al (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1):139–150PubMedCrossRef

28.

Taphoorn MJ, Claassens L, Aaronson NK et al (2010) An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46(6):1033–1040PubMedCrossRef

29.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels

30.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144PubMedCrossRef

31.

Frange P, Alapetite C, Gaboriaud G et al (2009) From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980–2000). J Neuro-oncology 95(2):271–279CrossRef

32.

Maddrey AM, Bergeron JA, Lombardo ER et al (2005) Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma. J Neurooncol 72(3):245–253PubMedCrossRef

33.

Kamran SC, Goldberg SI, Kuhlthau KA et al (2018) Quality of life in patients with proton-treated pediatric medulloblastoma: Results of a prospective assessment with 5-year follow-up. Cancer 124(16):3390–3400PubMedCrossRef

34.

van der Klaauw AA, Kars M, Biermasz NR et al (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol 69(5):775–784CrossRef

35.

Berkowitz O, Han YY, Talbott EO et al (2017) Gamma Knife Radiosurgery for Vestibular Schwannomas and Quality of Life Evaluation. Stereotact Funct Neurosurg 95(3):166–173PubMedCrossRef

36.

van de Poll-Franse LV, Mols F, Gundy CM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47(5):667–675PubMedCrossRef

37.

van Leeuwen M, Husson O, Alberti P et al (2018) Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes 16(1):114PubMedPubMedCentralCrossRef

38.

Kieffer V, Chevignard MP, Dellatolas G et al (2019) Intellectual, educational, and situation-based social outcome in adult survivors of childhood medulloblastoma. Dev Neurorehabil 22(1):19–26PubMedCrossRef

39.

EORTC Item Library. 2019. https://www.eortc.be/itemlibrary/.

40.

Grill J, Renaux VK, Bulteau C et al (1999) Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 45(1):137–145PubMedCrossRef

41.

Kieffer-Renaux V, Bulteau C, Grill J, Kalifa C, Viguier D, Jambaque I (2000) Patterns of neuropsychological deficits in children with medulloblastoma according to craniospatial irradiation doses. Dev Med Child Neurol 42(11):741–745PubMedCrossRef

42.

Moxon-Emre I, Bouffet E, Taylor MD et al (2014) Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol 32(17):1760–1768PubMedCrossRef

43.

Palmer SL, Goloubeva O, Reddick WE et al (2001) Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol 19(8):2302–2308PubMedCrossRef

44.

Klein M, Heimans JJ, Aaronson NK et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet (London, England) 360(9343):1361–1368CrossRef

45.

King AA, Seidel K, Di C et al (2017) Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro-oncology 19(5):689–698PubMed

46.

Salloum R, Chen Y, Yasui Y et al (2019) Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: a report from the Childhood Cancer Survivor Study. J Clin Oncol 37(9):731–740PubMedPubMedCentralCrossRef

47.

Michalski J, Vezina G, Burger P et al (2016) Preliminary results of COG ACNS0331: A phase III trial of involved field radiotherapy (IFRT) and low dose craniospinal irradiation (LD-CSI) with chemotherapy in average risk medulloblastoma: a report from the children's oncology group. Neuro-Oncology 96:937–938

48.

Padovani L, Sunyach MP, Perol D et al (2007) Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 68(2):433–440PubMedCrossRef

49.

Packer RJ, Gajjar A, Vezina G et al (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202–4208PubMedCrossRef

50.

Boele FW, Zant M, Heine EC et al (2014) The association between cognitive functioning and health-related quality of life in low-grade glioma patients. Neuro-oncology Pract 1(2):40–46CrossRef

51.

Habets EJ, Dirven L, Wiggenraad RG et al (2016) Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro-oncology 18(3):435–444PubMedCrossRef

52.

Herrlinger U, Schafer N, Fimmers R et al (2017) Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143(9):1815–1821PubMedCrossRef

53.

Reijneveld JC, Taphoorn MJ, Coens C et al (2016) Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17(11):1533–1542PubMedCrossRef

54.

Taphoorn MJ, Henriksson R, Bottomley A et al (2015) Health-related quality of life in a randomized phase iii study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 33(19):2166–2175PubMedCrossRef

55.

Renovanz M, Hechtner M, Kohlmann K et al (2018) Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out. Neuro-oncology Pract 5(2):129–138CrossRef

56.

Vordermark D (2007) Avoiding bias in the prospective evaluation of patients with brain metastases. J Clin Oncol 25(25):4023PubMedCrossRef

57.

Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R (2003) Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol 63(2):179–186PubMedCrossRef

58.

Armstrong TS, Ying Y, Wu J et al (2015) The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. Neuro-oncology 17(8):1114–1120PubMedPubMedCentralCrossRef

59.

Klein M, Engelberts NH, van der Ploeg HM et al (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54(4):514–520PubMedCrossRef

60.

Dirven L, van den Bent MJ, Bottomley A et al (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 51(10):1321–1330PubMedCrossRef

61.

Oyefiade A, Erdman L, Goldenberg A et al (2019) PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. J Neurooncol 142(1):39–48PubMedCrossRef

Title: Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study
Authors: Linda Dirven
Ralf Luerding
Dagmar Beier
Elisabeth Bumes
Christiane Reinert
Clemens Seidel
Matteo Mario Bonsanto
Michael Bremer
Stefan Rieken
Stephanie E. Combs
Ulrich Herrlinger
Corinna Seliger
Holger Kuntze
Regine Mayer-Steinacker
Annette Dieing
Claudius Bartels
Oliver Schnell
Astrid Weyerbrock
Sabine Seidel
Oliver Grauer
Minou Nadji-Ohl
Frank Paulsen
Michael Weller
Wolfgang Wick
Peter Hau
Publication date: 01-05-2020
Publisher: Springer US
Keywords: Medulloblastoma
Medulloblastoma
Medulloblastoma
Brain Tumor
Published in: Journal of Neuro-Oncology / Issue 1/2020
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03502-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Brain metastases resection cavity radio—surgery based on T2-weighted MRI: technique assessment

Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone

Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma

Resection versus biopsy in the treatment of multifocal glioblastoma: a weighted survival analysis

Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease

Correction to: Chemoradiation in elderly patients with glioblastoma from the multi‑institutional GBM‑molRPA cohort: is short‑course radiotherapy enough or is it a matter of selection?